Synthesis and Evaluation of Hydrophilic Linkers for Antibody-Maytansinoid Conjugates

被引:147
|
作者
Zhao, Robert Y. [1 ]
Wilhelm, Sharon D. [1 ]
Audette, Charlene [1 ]
Jones, Gregory [1 ]
Leece, Barbara A. [1 ]
Lazar, Alexandru C. [1 ]
Goldmacher, Victor S. [1 ]
Singh, Rajeeva [1 ]
Kovtun, Yelena [1 ]
Widdison, Wayne C. [1 ]
Lambert, John M. [1 ]
Chari, Ravi V. J. [1 ]
机构
[1] ImmunoGen Inc, Waltham, MA 02451 USA
关键词
CALICHEAMICIN CONJUGATE; MULTIDRUG-RESISTANCE; DRUG-RESISTANCE; CANCER; CELLS; DOXORUBICIN; ACID; TRANSPORTERS; CHEMOTHERAPY; SPECIFICITY;
D O I
10.1021/jm2002958
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The synthesis and biological evaluation of hydrophilic heterobifunctional cross-linkers for conjugation of antibodies with highly cytotoxic agents are described. These linkers contain either a negatively charged sulfonate group or a hydrophilic, noncharged PEG group in addition to an amine-reactive N-hydroxysuccinimide (NHS) ester and sulfhydryl reactive termini. These hydrophilic linkers enable conjugation of hydrophobic organic molecule drugs, such as a maytansinoid, at a higher drug/antibody ratio (DAR) than hydrophobic SPDB and SMCC linkers used earlier without triggering aggregation or loss of affinity of the resulting conjugate. Antibody maytansinoid conjugates (AMCs) bearing these sulfonate- or PEG-containing hydrophilic linkers were, depending on the nature of the targeted cells, equally to more cytotoxic to antigen-positive cells and equally to less cytotoxic to antigen-negative cells than conjugates made with SPDB or SMCC linkers and thus typically displayed a wider selectivity window, particularly against multidrug resistant (MDR) cancer cell lines in vitro and tumor xenograft models in vivo.
引用
收藏
页码:3606 / 3623
页数:18
相关论文
共 50 条
  • [31] Negatively-charged sulfonate group in linker improves potency of antibody-maytansinoid conjugates against multidrug-resistant cancer cells
    Kovtun, Y.
    Jones, G.
    Audette, C.
    Mayo, M.
    Leece, B.
    Zhao, R.
    Clancy, L.
    Sun, X.
    Chari, R.
    Singh, R.
    EJC SUPPLEMENTS, 2010, 8 (07): : 76 - 77
  • [32] Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers
    Gregson, Stephen J.
    Masterson, Luke A.
    Wei, Binqing
    Pillow, Thomas H.
    Spencer, Susan D.
    Kang, Gyoung-Dong
    Yu, Shang -Fan
    Raab, Helga
    Lau, Jeffrey
    Li, Guangmin
    Phillips, Gail D. Lewis
    Gunner-Toste, Janet
    Safina, Brian S.
    Ohri, Rachana
    Darwish, Martine
    Kozak, Katherine R.
    dela Cruz-Chuh, Josefa
    Poison, Andrew
    Flygare, John A.
    Howard, Philip W.
    JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (23) : 9490 - 9507
  • [33] BIOT 320-Characterization of antibody maytansinoid conjugates
    Krishnamurthy, Rajesh
    Lazar, Alex
    Bartlett, Lizz
    Chen, Xuan
    Fleming, Michael
    Leung, Pui-King Amy
    Amphlett, Godfrey
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
  • [34] Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer (vol 35, 70, 2016)
    Feng, Liang
    Yao, Hang-Ping
    Sharma, Sharad
    Zhou, Yong-Qing
    Zhou, Jianwei
    Zhang, Ruiwen
    Wang, Ming-Hai
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2016, 35
  • [35] Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates
    Catcott, Kalli C.
    McShea, Molly A.
    Bialucha, Carl Uli
    Miller, Kathy L.
    Hicks, Stuart W.
    Saxena, Parmita
    Gesner, Thomas G.
    Woldegiorgis, Mikias
    Lewis, Megan E.
    Bai, Chen
    Fleming, Michael S.
    Ettenberg, Seth A.
    Erickson, Hans K.
    Yoder, Nicholas C.
    MABS, 2016, 8 (03) : 513 - 523
  • [36] Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment
    Yao, Hang-Ping
    Feng, Liang
    Zhou, Jian-Wei
    Zhang, Rui-Wen
    Wang, Ming-Hai
    AMERICAN JOURNAL OF CANCER RESEARCH, 2016, 6 (05): : 937 - +
  • [37] Preclinical evaluation of IMGN853, an anti-FOLR1 antibody-maytansinoid conjugate, as a potential therapeutic for ovarian cancer
    Whiteman, Kathleen R.
    Johnson, Holly A.
    Xu, Shanqin
    Carrigan, Christina N.
    Ab, Olga
    Pinkas, Jan
    CANCER RESEARCH, 2011, 71
  • [38] Synthesis and evaluation of site-specific antibody-drug conjugates using conformationally restricted linkers
    Pedzisa, Lee
    Roush, William R.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [39] IN VITRO METABOLISM OF THE MAYTANSINOID PAYLOADS USED FOR ANTIBODY DRUG CONJUGATES
    Davis, John A.
    Rock, Dan A.
    Rock, Brooke M.
    DRUG METABOLISM REVIEWS, 2015, 47 : 185 - 186
  • [40] The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates
    Erickson, Hans K.
    Phillips, Gail D. Lewis
    Leipold, Douglas D.
    Provenzano, Carmela A.
    Mai, Elaine
    Johnson, Holly A.
    Gunter, Bert
    Audette, Charlene A.
    Gupta, Manish
    Pinkas, Jan
    Tibbitts, Jay
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (05) : 1133 - 1142